

July 4, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 543322

To,
The Manager - Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLS

Dear Sir/Madam,

Sub: Intimation under Regulations 30A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “SEBI LODR Regulations”) read with paragraph 5A of Part A of Schedule III of the SEBI LODR Regulations

Further to our intimation dated September 21, 2023, we wish to inform you, under Regulations 30A of the SEBI LODR Regulations read with paragraph 5A of Part A of Schedule III of the SEBI LODR Regulations, that we have entered into a letter agreement dated July 4, 2024 with Glenmark Pharmaceuticals Limited (the “**Seller**”) and Nirma Limited (the “**Agreement**”) which, *inter alia*, amends the earlier share purchase agreement dated September 21, 2023 (the “**SPA**”).

Details of Letter Agreement are set out in **Annexure I**.

This is for your information and records.

Yours faithfully,
For Glenmark Life Sciences Limited

Rudalf Corriea
Company Secretary & Compliance Officer

Annexure I

In case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange(s):

i. name of parties to the agreement;	Glenmark Life Sciences Limited (the “ Company ”), Glenmark Pharmaceuticals Limited (the “ Seller ”) and Nirma Limited
ii. nature of the agreement;	An agreement has been entered into by the Company, the Seller and Nirma Limited on July 4, 2024 (the “ Agreement ”) to amend the share purchase agreement dated September 21, 2023 (the “ SPA ”).
iii. date of execution of the agreement;	July 4, 2024
iv. details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier);	<p>Clause 6.11 of the SPA imposed a contractual restriction on the Seller to not sell, transfer or otherwise dispose of 9,609,571 Equity Shares of the Company (the “Current Seller Shareholding”) to any person until the earlier of: (a) a period of 1 (one) year from the closing date of the SPA; and (b) expiry of 1 (one) month from the date of compliance with the minimum public shareholding requirements by the Company and Nirma Limited.</p> <p>The Agreement dated July 4, 2024 has waived this contractual restriction imposed on the Seller. Provided however that if the Seller is not able to complete the sale of the Current Seller Shareholding or any portion thereof, in one or more tranches, within a mutually agreed period set out in the Agreement (“Proposed Sale Period”), the restrictions under Clause 6.11 of the SPA shall be reinstated with effect from the earlier of (i) the day immediately following the expiry of the Proposed Sale Period, and (ii) the date of the receipt of the last approval from the stock exchanges for reclassification of the Seller and Mr. Glenn Mario Saldanha from the “promoter and promoter group” to “public”, respect to any remaining shareholding of the Seller in the Company.</p> <p>The restriction on sale has been waived in order to facilitate compliance with the minimum public shareholding requirements.</p> <p>There will be no change in the management or control of the Company pursuant to the Agreement.</p>
v. reasons for rescission and impact thereof (including impact on management or control and on the restriction or liability quantified earlier).	Not applicable

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India.

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur - 413 213, India.

T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com